Бібліографічний опис:
1. Chauhan, S. Comprehensive review of coronavirus disease 2019 (COVID-19). Biomed. J. 2020,
https://doi.org/10.1016/j.bj.2020.05.023
2. Harapan, H.; Itoh, N.; Yufika, A.; Winardi, W.; Keam, S.; Te, H.; Megawati, D.; Hayati, Z.; Wagner, A.L.;
Mudatsir, M. Coronavirus disease 2019 (COVID-19): A literature review. Journal of Infection and Public
Health 2020, 13, 667-673, https://doi.org/10.1016/j.jiph.2020.03.019.
3. Tay, M.Z.; Poh, C.M.; Rénia, L.; MacAry, P.A.; Ng, L.F.P. The trinity of COVID-19: immunity,
inflammation and intervention. Nature Reviews Immunology 2020, 20, 363-374,
https://doi.org/10.1038/s41577-020-0311-8
4. Alsayed, R.; Kadhom, M.; Yousif, E.; Sabir, D.K., An Epidemiological Characteristic of the COVID-19
Among Children, Lett. Appl. NanoBioSci. 2020, 9, 1156–1164,
https://doi.org/10.33263/LIANBS93.11561164
5. Figueroa-Valverde, L.; Díaz-Cedillo, F.; López-Ramos, M.; Rosas-Nexticapa, M.; Mateu-Armad, M.V.;
Garcimarrero, R.A.; Cauich-Carrillo, R.; Ortiz-Ake, Y. Design and Synthesis of Five Cyclobuta-1,3-Dien-
1-yl-Steroid Derivatives to Evaluate Their Theoretical Activity Against COVID-19. Lett. Appl. NanoBioSci.
2020, 9, 1177–1187, https://doi.org/10.33263/LIANBS93.11771187
6. Hosny, N.M.; Sherif, Y. Molecular Docking Study on Some Isonicotinoyl Hidrazide Derivatives as Potencial
Inhibitors of COVID-19. Lett. Appl. NanoBioSci. 2020, 9, 1217–1224,
https://doi.org/10.33263/LIANBS93.12171224
7. Eastman, R.T.; Roth, J.S.; Brimacombe, K.R.; Simeonov, A.; Shen, M.; Patnaik, S.; Hall, M.D. Remdesivir.
A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of
COVID-19. ACS Cent. Sci. 2020, 6, 672-683, https://doi.org/10.1021/acscentsci.0c00489.
8. Grein, J.; Ohmagari, N.; Shin, D.; Diaz, G.; Asperges, E.; Castagna, A.; Feldt, T.; Green, G.; Green, M.L.;
Lescure, F.-X.; Nicastri, E.; Oda, R.; Yo, K.; Quiros-Roldan, E.; Studemeister, A.; Redinski, J.; Ahmed, S.;
Bernett, J.; Chelliah, D.; Chen, D.; Chihara, S.; Cohen, S.H.; Cunningham, J.; D’Arminio Monforte, A.;
Ismail, S.; Kato, H.; Lapadula, G.; L’Her, E.; Maeno, T.; Majumder, S.; Massari, M.; Mora-Rillo, M.; Mutoh,
Y.; Nguyen, D.; Verweij, E.; Zoufaly, A.; Osinusi, A.O.; DeZure, A.; Zhao, Y.; Zhong, L.; Chokkalingam,
A.; Elboudwarej, E.; Telep, L.; Timbs, L.; Henne, I.; Sellers, S.; Cao, H.; Tan, S.K.; Winterbourne, L.; Desai,
P.; Mera, R.; Gaggar, A.; Myers, R.P.; Brainard, D.M.; Childs, R.; Flanigan, T. Compassionate Use of
Remdesivir for Patients with Severe COVID-19. New Engl. J. Med. 2020, 382, 2327–2336,
https://doi.org/10.1056/NEJMoa2007016.
9. Beigel, J.H.; Tomashek, K.M.; Dodd, L.E.; Mehta, A.K.; Zingman, B.S.; Kalil, A.C.; Hohmann, E.; Chu,
H.Y.; Luetkemeyer, A.; Kline, S.; Lopez de Castilla, D.; Finberg, R.W.; Dierberg, K.; Tapson, V.; Hsieh,
L.; Patterson, T.F.; Paredes, R.; Sweeney, D.A.; Short, W.R.; Touloumi, G.; Lye, D.C.; Ohmagari, N.; Oh,
M.-d.; Ruiz-Palacios, G.M.; Benfield, T.; Fätkenheuer, G.; Kortepeter, M.G.; Atmar, R.L.; Creech, C.B.;
Lundgren, J.; Babiker, A.G.; Pett, S.; Neaton, J.D.; Burgess, T.H.; Bonnett, T.; Green, M.; Makowski, M.;
Osinusi, A.; Nayak, S.; Lane, H.C. Remdesivir for the Treatment of COVID-19–Preliminary Report. New
Engl. J. Med., 2020, https://doi.org/10.1056/NEJMoa2007764.
10. Jorgensen, S.C.J.; Kebriaei, R.; Dresser, L.D. Remdesivir: Review of Pharmacology, Pre-Clinical Data and
Emerging Clinical Experience for COVID-19. Pharmacology, J. Hum Pharm. Drug. Ther. 2020, 40,
https://doi.org/10.1002/phar.2329.
11. Azevedo, T.C.P.D.; Azevedo, P.C.P.D.; Silveira Filho, R.N.; Carvalho, A.R.V.S.D.; Cezarotti Filho, M.L.;
Barbosa, F.T.; Sousa-Rodrigues, C.F.D.; Matos-Rocha, T.J.; Ramos, F.W.D.S. Use of remdesivir for patients
with Covid-19: a review article. J Revista da Associação Médica Brasileira 2020, 66, 838-841,
https://doi.org/10.1590/1806-9282.66.6.838
